Researchers are exploring whether anti-IL-17 biologics, a class of drugs originally developed to treat psoriasis, could offer a breakthrough for patients struggling with severe nodulocystic acne. While IL-17 inhibitors like ixekizumab and secukinumab have proven highly effective for psoriasis—with 82-83% of patients achieving significant symptom improvement—preliminary evidence suggests these same drugs may address the underlying inflammatory pathways driving severe, treatment-resistant acne. However, it’s important to note that as of 2026, formal clinical trials specifically demonstrating efficacy for nodulocystic acne remain limited, and the field is still in the early stages of investigation.
The connection between these two skin conditions isn’t coincidental. Both psoriasis and severe acne involve an overactive Th17 immune response, where IL-17 drives persistent inflammation. The difference is that while IL-17 inhibitors like bimekizumab have shown promising results in case reports of acne conglobata (the most severe form of acne), we still lack the large-scale controlled trials needed to confirm whether these drugs should become a standard treatment option. The evidence available today is encouraging but preliminary.
Table of Contents
- How IL-17 Inhibitors Work and Why Psoriasis Success Prompted Acne Research
- Current Evidence from Trials and Case Reports—What We Know and What Remains Unknown
- The Inflammatory Pathway Connection—Why Psoriasis Success Suggested Acne Potential
- Why IL-17 Inhibitors Haven’t Yet Become Standard Acne Treatment
- Safety Considerations and the Risk of Immunosuppression
- Netakimab, Secukinumab, and Other Candidates in the Pipeline
- What Dermatologists Are Watching and What’s Next
- Conclusion
How IL-17 Inhibitors Work and Why Psoriasis Success Prompted Acne Research
IL-17 is a cytokine—a signaling molecule—that tells immune cells to trigger inflammation. By blocking IL-17, these biologics essentially turn down the inflammatory volume in the body. For psoriasis, this approach has been remarkably successful. Ixekizumab achieved an 83% response rate at week 12 of treatment, while secukinumab reached 82%, and brodalumab matched that at 82%.
These drugs work by targeting the IL-17 pathway at different points: some block the IL-17A protein directly, while others like bimekizumab take a dual approach, inhibiting both IL-17A and IL-17F. Severe acne, particularly nodulocystic acne, involves a different pathogen (Cutibacterium acnes rather than the systemic immune triggers in psoriasis) but operates through a similar inflammatory mechanism. When bacteria colonize the sebaceous gland, the immune system launches a Th17-mediated response that creates the large, painful nodules and cysts characteristic of this form of acne. Early case reports suggest that if you can suppress the IL-17 pathway in acne patients, you might reduce the inflammatory cascade that makes these lesions so severe and difficult to treat.
Current Evidence from Trials and Case Reports—What We Know and What Remains Unknown
Bimekizumab, a newer dual IL-17 inhibitor currently in Phase III trials for psoriasis, has generated the most attention in acne circles due to scattered case reports showing improvement in acne conglobata. Acne conglobata is the most severe form of acne and is often resistant to standard treatments like isotretinoin, making any potential new approach meaningful for affected patients. However, these are individual case reports, not controlled trials where researchers assign patients to either the drug or a placebo and measure outcomes systematically.
The critical limitation here is that no published clinical trials have yet demonstrated that an IL-17 inhibitor originally developed for psoriasis can effectively treat nodulocystic acne in a controlled setting. While the biologic plausibility is strong—IL-17 is absolutely involved in severe acne inflammation—clinical trial data is what regulators and dermatologists need to recommend a drug for a new indication. Until those trials are completed and published, IL-17 inhibitors remain off-label experimental options rather than established treatments for acne.
The Inflammatory Pathway Connection—Why Psoriasis Success Suggested Acne Potential
The reason dermatologists began looking at IL-17 inhibitors for acne stems from growing understanding of the Th17 immune response in skin disease. Th17 cells produce IL-17, which recruits immune cells to the skin and amplifies inflammation. In psoriasis, this runaway inflammatory response leads to the thick, scaly plaques that characterize the disease.
In severe acne, the same pathway—activated by bacterial antigen from C. acnes—produces the deep nodular lesions that often leave permanent scarring. A 2025 PMC research article on acne treatment highlighted the IL-17/Th17 pathway as a key inflammatory driver in severe acne phenotypes, suggesting that blocking this pathway could theoretically interrupt the most damaging phase of the disease. The parallel is compelling: if an anti-IL-17 drug can quiet psoriatic inflammation so effectively, why not severe acne? The answer, so far, is that the leap from psoriasis to acne hasn’t been formally tested at the clinical trial level, even though the underlying biology points in a promising direction.
Why IL-17 Inhibitors Haven’t Yet Become Standard Acne Treatment
Several practical and regulatory barriers explain why anti-IL-17 biologics remain experimental for acne, despite theoretical promise. First, these are expensive infusion or injection therapies—far more costly than oral antibiotics, retinoids, or even isotretinoin. For acne to be treated with a biologic, the trial data would need to show dramatic superiority over existing options, not just modest improvement.
Second, acne is common and usually manageable with current treatments; psoriasis, by contrast, is harder to treat and affects quality of life more severely, which justifies the cost and complexity of biologic therapy. The comparison matters: isotretinoin (Accutane) already cures most cases of severe acne, although it carries risks of birth defects and requires intensive monitoring. For a biologic to gain traction, it would need to either work as well as isotretinoin with fewer side effects, or succeed in the rare isotretinoin-resistant cases. The case reports of bimekizumab working in acne conglobata—which is notoriously resistant—suggest the drug might fill that niche, but this needs formal proof through controlled trials before prescribing physicians can confidently recommend it.
Safety Considerations and the Risk of Immunosuppression
Anti-IL-17 biologics carry known safety concerns that are acceptable for serious conditions like psoriasis but require careful consideration in acne. By dampening the IL-17 pathway, these drugs can increase susceptibility to infections, particularly fungal infections like candidiasis. Patients on these medications are typically monitored for signs of infection and may need to delay or interrupt treatment during acute illness.
For a chronic cosmetic condition like acne, even if severe, dermatologists would weigh these risks seriously. Additionally, long-term use of immunosuppressive therapy carries theoretical risks of malignancy that remain incompletely understood. The psoriasis trials have been reassuring so far, but decades of follow-up data don’t yet exist for some of these newer agents. Using an IL-17 inhibitor to treat acne—especially in young patients who could take the drug for years—would require strong evidence of benefit to justify accepting immunosuppression as a tradeoff.
Netakimab, Secukinumab, and Other Candidates in the Pipeline
Beyond bimekizumab, other anti-IL-17 agents are advancing through development that could eventually be studied in acne. Netakimab, an IL-17A inhibitor, is in Phase III trials for psoriasis and might eventually be tested in severe acne if the mechanism continues to show promise.
Secukinumab and ixekizumab, already FDA-approved for psoriasis and other indications, are sometimes used off-label by dermatologists for difficult cases, but no controlled acne trials with these agents have been published. The existence of a pipeline of IL-17 inhibitors means that if one proves effective in acne, regulatory pathways might accelerate for the others.
What Dermatologists Are Watching and What’s Next
Dermatologists are monitoring the emerging acne data closely, particularly reports of bimekizumab in acne conglobata. Professional organizations are likely to take note when the first controlled trial results become available, even if that trial is small. The field is positioned at an inflection point: if a well-designed trial demonstrates that an IL-17 inhibitor works better than placebo or than a comparator treatment in severe acne, interest in this therapeutic class would surge, and pharmaceutical companies would be incentivized to pursue FDA approval for the acne indication.
In the meantime, patients with treatment-resistant severe acne might discuss off-label IL-17 inhibitor use with their dermatologist, particularly in cases where isotretinoin has failed or is contraindicated. This conversation would acknowledge the lack of formal acne trial data while recognizing the compelling biological rationale. As we move deeper into 2026, the first published results from dedicated acne trials could reshape how dermatologists approach the most severe cases.
Conclusion
Anti-IL-17 biologics represent a fascinating intersection of dermatology’s expanding understanding of skin inflammation and the search for better tools to treat severe acne. The success of these drugs in psoriasis, where 82-83% of patients achieve significant improvement, has opened the door to investigation in acne—particularly the severe, cystic forms that resist other treatments. Early case reports, especially with bimekizumab in acne conglobata, suggest the biologic mechanism is sound.
However, the critical distinction between promise and proven efficacy remains. As of now, formal clinical trials demonstrating that an anti-IL-17 biologic effectively treats nodulocystic acne are still lacking. Patients and dermatologists should interpret the current evidence as encouraging but preliminary—a signal that warrants formal investigation, not yet a reason to pursue these expensive, immunosuppressive drugs as first-line acne therapy. The coming years will likely bring trial data that either validates this therapeutic approach or clarifies why the psoriasis success story doesn’t fully translate to acne treatment.
You Might Also Like
- New JAK Inhibitor Cream in Clinical Trials…Originally for Eczema Now Being Tested for Severe Inflammatory Acne
- New CRISPR Gene Therapy for Acne in Clinical Trials…Researchers Exploring Genetic Modification of Sebaceous Glands
- New Bacteriophage Therapy in Clinical Trials…Uses Viruses That Target P. Acnes Bacteria Without Antibiotic Resistance
